Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Assets (2022 - 2025)

Zentalis Pharmaceuticals (ZNTL) has 3 years of Assets data on record, last reported at $430.3 million in Q4 2024.

  • For Q4 2024, Assets fell 22.0% year-over-year to $430.3 million; the TTM value through Dec 2024 reached $430.3 million, down 22.0%, while the annual FY2024 figure was $430.3 million, 22.0% down from the prior year.
  • Assets reached $430.3 million in Q4 2024 per ZNTL's latest filing, down from $450.7 million in the prior quarter.
  • Across five years, Assets topped out at $621.4 million in Q2 2023 and bottomed at $430.3 million in Q4 2024.
  • Average Assets over 3 years is $520.4 million, with a median of $529.2 million recorded in 2022.
  • Peak YoY movement for Assets: rose 9.44% in 2023, then dropped 22.0% in 2024.
  • A 3-year view of Assets shows it stood at $529.2 million in 2022, then rose by 4.25% to $551.7 million in 2023, then decreased by 22.0% to $430.3 million in 2024.
  • Per Business Quant database, its latest 3 readings for Assets were $430.3 million in Q4 2024, $450.7 million in Q3 2024, and $491.7 million in Q2 2024.